Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Interventional × Fruquintinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1175 Neoplasms 885 Carcinoma, Non-Small-Cell Lung 750 Prostatic Neoplasms 655 Colorectal Neoplasms 579 Lung Neoplasms 473 Leukemia, Myeloid, Acute 413 Pancreatic Neoplasms 379 Neoplasm Metastasis 371 Carcinoma, Hepatocellular 355 Ovarian Neoplasms 341 Multiple Myeloma 340 Stomach Neoplasms 329 Recurrence 315 Squamous Cell Carcinoma of Head and Neck 276 Melanoma 261 Uterine Cervical Neoplasms 252 Brain Neoplasms 237 Triple Negative Breast Neoplasms 234 Precursor Cell Lymphoblastic Leukemia-Lymphoma 231 Head and Neck Neoplasms 228 Glioblastoma 219 Lymphoma 218 Endometrial Neoplasms 208 Esophageal Neoplasms 206 Rectal Neoplasms 197 Sarcoma 187 Carcinoma, Renal Cell 183 Lymphoma, Non-Hodgkin 173 Colonic Neoplasms 173

Interventions

raltitrexed 1 potassium oxonate 1 gimeracil 1 Tegafur 1 S 1 (combination) 1 HMPL-013 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06427005 2025-01-22

Fruquintinib Plus S-1 and Raltitrexed (RSF) for MCRC

West China Hospital

Phase 2 Recruiting

Fruquintinib

Data powered by HemOnc (CC BY 4.0) Colophon ⚡